Cargando...
Phase II Study Evaluating the Combination of Sorafenib and Temsirolimus in the Treatment of Radioactive Iodine-Refractory Thyroid Cancer
BACKGROUND: Patients with recurrent and/or metastatic radioactive iodine refractory thyroid carcinomas (RAI-TC) have limited treatment options. Sorafenib, an oral kinase inhibitor, is FDA approved for the treatment of RAI-TC but demonstrated low response rates (12.2%) as a single agent in the first...
Guardado en:
| Publicado en: | Cancer |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5650535/ https://ncbi.nlm.nih.gov/pubmed/28662274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30861 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|